Yuimedi raises ¥600M to build Japan's medical data infrastructure
What's the deal? Tokyo-based Yuimedi, which builds infrastructure for medical data utilisation, has closed the second tranche of its latest funding round, bringing the total to ¥600M (roughly $4M). The second close of ¥200M came from Norinchukin Capital and Darwin Venture Management. The first close was completed in February 2026.
Yuimedi, founded in 2020 by Emiri Grimes, runs three business lines: YuiData, a real-world data service for pharma companies using electronic health records from partner hospitals; YuiQuery, a healthcare-focused AI tool that lets users query medical data in natural language; and a data standardisation business that converts real-world data into the global OMOP CDM format.
The fresh capital will go toward hiring — business development and sales staff for YuiData, and engineers for YuiQuery.
Why now? Yuimedi has been building momentum. Since the first close in February, it expanded its network of data-providing hospitals to roughly 30 facilities. In April, it provided technical support for an OMOP conversion pilot led by NECDealroom has a profile for this one. Try Dealroom →, Ehime University, and FedAna — part of Japan's push toward a national medical information platform and a "Japanese EHDS" (European Health Data Space equivalent).
Government policy is creating tailwinds. Japan is actively promoting the standardisation and secondary use of medical data, giving companies like Yuimedi a structural advantage.
What could go wrong? Medical data is among the most sensitive information that exists. Building trust with hospitals takes time, and any data breach or privacy misstep could be catastrophic. The regulatory landscape is also evolving — new rules could either accelerate or complicate Yuimedi's business.
Competition is another risk. As AI-driven healthcare data platforms attract more attention globally, larger players like NEC could move from partner to competitor.
The signal: Yuimedi's raise underscores a widening global conviction that, as AI commoditises software, durable competitive advantage in healthcare will belong to those who control access to high-quality, standardised medical data. Japan's vast electronic health records remain largely untapped for secondary use, and government initiatives like the national medical information platform are now actively lowering barriers to change. For an early growth-stage company, locking in ~30 hospital partnerships and embedding itself in nationally backed OMOP standardisation pilots positions Yuimedi as foundational infrastructure — not easily replicated by later entrants.
Read more: prtimes.jp
